ABT and BSX: A Look at Segmental Performance in Fiscal 2019

Abbott Laboratories’ Segmental performance

In its first-quarter earnings conference call, Abbott Laboratories (ABT) guided for mid-single-digit growth for its established pharmaceuticals business in the second quarter, which includes mid to high single digit growth in key emerging markets but a decline in EPD sales in other markets due to the continuation of low-margin supply agreements for non-core products.

In its first-quarter earnings conference call, Abbott Laboratories guided for mid single digit revenue growth for its nutrition business, mid to high single digit revenue growth for its legacy diagnostics business, and low to mid single digit revenue growth for its Rapid Diagnostics business in the second quarter. The company also expects its medical devices business to grow its revenues YoY by high single digits in the second quarter driven by double-digit growth in various areas of this business.

ABT and BSX: A Look at Segmental Performance in Fiscal 2019

Ready to put your morning scrolling to use? Sign up for Bagels & Stox, our witty take on the top market and investment news straight to your inbox! Whether you’re a serious investor or just want to be informed, Bagels & Stox will be your favorite email.

Boston Scientific’s segmental performance

In its fourth-quarter earnings conference call, Boston Scientific (BSX) highlighted the ongoing robust performance of its hemostasis franchise, a part of its endoscopy segment in its infection prevention and pathology segments. The company also expects its global endoscopy business to benefit from the launch of four new products such as Orisa gel for endoluminal surgery, SpyGlass DS II for pancreatic biliary procedures, Orca pod single-use valves, and Exalt-D single use duodenoscope, in fiscal 2019.

In its fourth-quarter earnings conference call, Boston Scientific also highlighted the robust performance of its Urology and Pelvic Health business driven organically by Single-Use Digital Ureteroscope, LithoVue in its kidney stone indication, and inorganically by tuck-in acquisitions such as those of NxThera, nVision, and Augmenix.

The company expressed confidence in the ability of its neuromodulation business to post a robust performance in fiscal 2019 driven by solid uptake across key markets and a broad portfolio of innovative products.